{"success":true,"data":{"pressRelease":{"id":"176948","rtpr_id":"nGNX1mMY40-20261022","ticker":"NTHI","exchange":"NASDAQ","all_tickers":["NTHI"],"title":"NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy","author":"Globe Newswire","published_at":"2026-10-22T12:00:02.919Z","article_body":"CALABASAS, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies\nHoldings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a\nclinical-stage biopharmaceutical company developing therapies for central\nnervous system (CNS) cancers, today announced that it will be featured on\nHealth Uncensored with Dr. Drew, a national health television series hosted by\nDr. Drew Pinsky, in a segment on non-invasive approaches to delivering\ninvestigational therapies to brain tumors.\n\nFox Business Network will carry the segment on Sunday, October 25, 2026, at\n5:30 p.m. ET / 2:30 p.m. PT. Air dates and times are subject to change.\n\nAmir F. Heshmatpour, Executive Chairman, President and Chief Executive\nOfficer, and Thomas Chen, MD, PhD, Founder, Chief Medical Officer and Chief\nScientific Officer of NeOnc, join Dr. Drew to discuss how NeOnc’s intranasal\napproach is designed to reach brain tumors directly, without the limitations\nof surgery and systemic chemotherapy.\n\nDuring the segment, Mr. Heshmatpour describes brain cancer as a growing\nproblem and discusses the Company’s investigational intranasal NEO100\nprogram, which is in clinical development in both adults and children.\nSpeaking about what the program could mean for patients, he says: “We\nbelieve that we will make a significant impact in the standard of care for\nadults and kids suffering with brain cancer.”\n\nAdditionally, in the segment, Dr. Chen explains how the same mechanism meant\nto protect the brain actually makes brain tumors so difficult to treat with\ntraditional approaches, and how NeOnc is working to overcome that challenge.\n\nNEO100 is a highly purified form of perillyl alcohol administered\nintranasally. Its delivery approach is designed to provide a non-invasive\nroute to the brain. NEO100 remains investigational, and its safety and\nefficacy have not been established.\n\nAbout Health Uncensored with Dr. Drew\n\nHealth Uncensored with Dr. Drew is a health and wellness program hosted by Dr.\nDrew Pinsky, a board-certified physician in Internal and Addiction Medicine,\nas well as a television host, author and public speaker. Dr. Drew engages with\na range of experts, thought leaders, celebrities and everyday people to\nprovide viewers with practical advice, evidence-based information and\ndiscussions about wellness, mental health and the importance of proactive\nhealth management.\n\nAbout NeOnc Technologies Holdings, Inc.\n\nNeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical\ncompany developing therapies for central nervous system cancers. Its\ninvestigational programs include intranasal NEO100 and oral NEO212. NEO212 has\ncompleted Phase 1 dose escalation and is advancing toward Phase 2 development.\nNeOnc exclusively licenses a worldwide portfolio of issued patents and pending\napplications from the University of Southern California related to NEO100,\nNEO212 and other drug candidates and delivery approaches.\n\nFor more information, visit https://neonc.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements, including statements\nregarding the Company’s clinical development programs and the clinical\npotential of NEO100. These statements reflect current expectations and involve\nrisks and uncertainties. NEO100 is investigational and has not been approved\nby any regulatory authority; future studies may not demonstrate safety or\nefficacy; clinical development remains subject to applicable clinical,\nregulatory and institutional requirements; and no regulatory pathway or\nmarketing approval is assured. Actual results may differ materially. Readers\nshould consider the risk factors described in the Company’s most recent\nfilings with the Securities and Exchange Commission. These statements speak\nonly as of the date of this release.\n\nThe Company undertakes no obligation to update forward-looking statements\nexcept as required by law.\n\n“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies\nHoldings, Inc.\n\nContacts\n\nCompany Contact:\ninfo@neonc.com\n\nInvestor Contact:\nJon Nugent\nJon Nugent Communications\njon@jonnugent.com\n205-566-3026\n\nThis press release was published by a CLEAR® Verified individual.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/24b1bfd4-b28d-443d-9ec2-0a30c1b76cee)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1mMY40-20261022","title":"NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy","author":"Globe Newswire","ticker":"NTHI","created":"2026-10-22T12:00:02.919Z","tickers":["NTHI"],"exchange":"NASDAQ","article_body":"CALABASAS, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies\nHoldings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a\nclinical-stage biopharmaceutical company developing therapies for central\nnervous system (CNS) cancers, today announced that it will be featured on\nHealth Uncensored with Dr. Drew, a national health television series hosted by\nDr. Drew Pinsky, in a segment on non-invasive approaches to delivering\ninvestigational therapies to brain tumors.\n\nFox Business Network will carry the segment on Sunday, October 25, 2026, at\n5:30 p.m. ET / 2:30 p.m. PT. Air dates and times are subject to change.\n\nAmir F. Heshmatpour, Executive Chairman, President and Chief Executive\nOfficer, and Thomas Chen, MD, PhD, Founder, Chief Medical Officer and Chief\nScientific Officer of NeOnc, join Dr. Drew to discuss how NeOnc’s intranasal\napproach is designed to reach brain tumors directly, without the limitations\nof surgery and systemic chemotherapy.\n\nDuring the segment, Mr. Heshmatpour describes brain cancer as a growing\nproblem and discusses the Company’s investigational intranasal NEO100\nprogram, which is in clinical development in both adults and children.\nSpeaking about what the program could mean for patients, he says: “We\nbelieve that we will make a significant impact in the standard of care for\nadults and kids suffering with brain cancer.”\n\nAdditionally, in the segment, Dr. Chen explains how the same mechanism meant\nto protect the brain actually makes brain tumors so difficult to treat with\ntraditional approaches, and how NeOnc is working to overcome that challenge.\n\nNEO100 is a highly purified form of perillyl alcohol administered\nintranasally. Its delivery approach is designed to provide a non-invasive\nroute to the brain. NEO100 remains investigational, and its safety and\nefficacy have not been established.\n\nAbout Health Uncensored with Dr. Drew\n\nHealth Uncensored with Dr. Drew is a health and wellness program hosted by Dr.\nDrew Pinsky, a board-certified physician in Internal and Addiction Medicine,\nas well as a television host, author and public speaker. Dr. Drew engages with\na range of experts, thought leaders, celebrities and everyday people to\nprovide viewers with practical advice, evidence-based information and\ndiscussions about wellness, mental health and the importance of proactive\nhealth management.\n\nAbout NeOnc Technologies Holdings, Inc.\n\nNeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical\ncompany developing therapies for central nervous system cancers. Its\ninvestigational programs include intranasal NEO100 and oral NEO212. NEO212 has\ncompleted Phase 1 dose escalation and is advancing toward Phase 2 development.\nNeOnc exclusively licenses a worldwide portfolio of issued patents and pending\napplications from the University of Southern California related to NEO100,\nNEO212 and other drug candidates and delivery approaches.\n\nFor more information, visit https://neonc.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements, including statements\nregarding the Company’s clinical development programs and the clinical\npotential of NEO100. These statements reflect current expectations and involve\nrisks and uncertainties. NEO100 is investigational and has not been approved\nby any regulatory authority; future studies may not demonstrate safety or\nefficacy; clinical development remains subject to applicable clinical,\nregulatory and institutional requirements; and no regulatory pathway or\nmarketing approval is assured. Actual results may differ materially. Readers\nshould consider the risk factors described in the Company’s most recent\nfilings with the Securities and Exchange Commission. These statements speak\nonly as of the date of this release.\n\nThe Company undertakes no obligation to update forward-looking statements\nexcept as required by law.\n\n“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies\nHoldings, Inc.\n\nContacts\n\nCompany Contact:\ninfo@neonc.com\n\nInvestor Contact:\nJon Nugent\nJon Nugent Communications\njon@jonnugent.com\n205-566-3026\n\nThis press release was published by a CLEAR® Verified individual.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/24b1bfd4-b28d-443d-9ec2-0a30c1b76cee)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-22T12:00:03.233193949Z","server_sent_at_ms":1792670403233},"received_at":"2026-10-22T12:00:03.290Z","source_url":null},"analysis":{"id":"164910","press_release_id":"176948","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["promotional media segment rather than data disclosure; NEO100 remains investigational with unestablished safety and efficacy"],"eventType":"other","narrative":"NeOnc Technologies will be featured on Health Uncensored with Dr. Drew, airing on Fox Business on Sunday, October 25 at 5:30 p.m. ET.\n\nExecutives will discuss the investigational intranasal NEO100 program, designed to reach brain tumors without surgery or systemic chemotherapy.\n\nThis is a promotional media appearance with no new clinical data, financial results, or regulatory milestones disclosed.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Promotional TV appearance -- no new data; watch for retail-driven volatility around the Sunday airing."},"keyFigures":{},"quotedText":"We believe that we will make a significant impact in the standard of care for adults and kids suffering with brain cancer.","namedEntities":{"people":[{"name":"Amir F. Heshmatpour","role":"Executive Chairman, President and CEO"},{"name":"Thomas Chen, MD, PhD","role":"Founder, Chief Medical Officer and Chief Scientific Officer"},{"name":"Dr. Drew Pinsky","role":"TV host, Health Uncensored"}],"products":["NEO100","NEO212","Health Uncensored with Dr. Drew"],"companies":[{"name":"NeOnc Technologies Holdings, Inc.","ticker":"NTHI"},{"name":"Fox Business Network","relationship":"media broadcaster"},{"name":"University of Southern California","relationship":"licensing partner"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Paid-style media appearance announcement (Health Uncensored with Dr. Drew on Fox Business) with no new clinical, financial, or regulatory data. Pure promotional visibility event."},"tickerRelevance":{"others":[],"primary":"NTHI"},"globalImportance":8,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"promotional media appearance","newInformation":false,"retailFavoriteBoost":"minor -- clinical-stage CNS biotech may draw retail interest"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"NeOnc Technologies will be featured on Health Uncensored with Dr. Drew, airing on Fox Business on Sunday, October 25 at 5:30 p.m. ET.\n\nExecutives will discuss the investigational intranasal NEO100 program, designed to reach brain tumors without surgery or systemic chemotherapy.\n\nThis is a promotional media appearance with no new clinical data, financial results, or regulatory milestones disclosed.","key_figures":{},"named_entities":{"people":[{"name":"Amir F. Heshmatpour","role":"Executive Chairman, President and CEO"},{"name":"Thomas Chen, MD, PhD","role":"Founder, Chief Medical Officer and Chief Scientific Officer"},{"name":"Dr. Drew Pinsky","role":"TV host, Health Uncensored"}],"products":["NEO100","NEO212","Health Uncensored with Dr. Drew"],"companies":[{"name":"NeOnc Technologies Holdings, Inc.","ticker":"NTHI"},{"name":"Fox Business Network","relationship":"media broadcaster"},{"name":"University of Southern California","relationship":"licensing partner"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-22T12:00:36.330Z","global_importance":8,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"promotional media appearance","newInformation":false,"retailFavoriteBoost":"minor -- clinical-stage CNS biotech may draw retail interest"}},"durationMs":5377,"modelName":"glm-5.3-flashx"}}